Last reviewed · How we verify

Apidra (INSULIN GLULISINE)

Sanofi · FDA-approved approved Recombinant protein Quality 55/100

Insulin glulisine lowers blood glucose by stimulating glucose uptake in muscles and fat, and by inhibiting liver glucose production.

Apidra, also known as INSULIN GLULISINE, is a small molecule insulin medication developed by Sanofi-Aventis US. It targets the insulin receptor to treat diabetes mellitus, a condition characterized by high blood sugar levels. Apidra was FDA-approved in 2004 and remains a branded medication. Key safety considerations include the risk of hypoglycemia, or low blood sugar, and potential allergic reactions. As a branded medication, Apidra is not yet available as a generic alternative.

At a glance

Generic nameINSULIN GLULISINE
SponsorSanofi
Drug classInsulin Analog [EPC]
TargetInsulin receptor
ModalityRecombinant protein
Therapeutic areaMetabolic
PhaseFDA-approved
First approval2004

Mechanism of action

Insulin glulisine helps regulate glucose levels in the body. It does this by promoting the absorption of glucose into muscle and fat tissues and by reducing the amount of glucose produced by the liver. Additionally, it prevents the breakdown of fats and proteins and supports protein synthesis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: